벤처 투자
Investing in OpenEvidence | How to Buy Pre-IPO Shares
Securities.io를 Google의 선호 소스에 추가
OpenEvidence is a private ai & data company. OpenEvidence develops an AI medical information platform designed to help clinicians search, synthesize, and apply evidence from medical literature at the point of care.
Private-market status: OpenEvidence remained private as of 2026년 8월 31일. A later report that it was considering another round was not treated as a closed financing. This guide was independently checked on 2026년 8월 31일.
What Is OpenEvidence?
OpenEvidence is a medical knowledge platform designed to answer clinicians’ questions at the point of care. Instead of asking doctors to search many journals and guidelines manually, the service synthesizes relevant evidence into a cited response and lets users inspect the underlying source material.
Its strategic asset is not only an AI interface but licensed, structured access to trusted medical content. OpenEvidence lists official relationships with The New England Journal of Medicine, JAMA Network, Nature, Cochrane, and the National Comprehensive Cancer Network, among other medical societies. Those agreements can improve answer quality and defensibility compared with systems trained mainly on the open web.
Adoption can be powerful because an accurate answer saves clinician time and can influence care immediately. The standard is correspondingly high: responses must remain current, represent uncertainty, surface citations, and avoid turning a research assistant into an unaccountable diagnostic system. Investors should distinguish rapid registered-user growth from durable workflow integration, recurring revenue, and documented clinical value.
OpenEvidence Funding and Valuation
The latest independently supportable financing was $250 million Series D. The associated valuation context was $12 billion. Funding amounts and valuations are different measures: a round amount is new or transferred capital, while a valuation is a negotiated price for a specific security at a point in time.
OpenEvidence Selected Funding Events
Selected disclosed financing amounts, USD; non-equity awards, grants, contracts, and unclosed rumors excluded.
Funding events 1–4
| Date | Round / Type | Amount | Reported Valuation | Method note |
|---|---|---|---|---|
| 2025-02 | Series A | $75M | $1B | Reported primary financing |
| 2025-07 | Series B | $210M | $3.5B | Primary financing |
| 2025-10 | Series C | $200M | $6B | Primary financing |
| 2026-01 | Series D | $250M | $12B | Primary financing |
Preferred shares, common shares, tender offers, and special-purpose-vehicle interests can carry different economics. A secondary transaction may provide liquidity to an existing holder without adding operating cash to OpenEvidence.
Investment Case for OpenEvidence
The investment case is best evaluated through four operating proof points rather than the size of the headline market alone.
Evidence synthesis at the point of care
A physician can ask a natural-language question and receive a concise, source-linked synthesis rather than a list of search results. The product’s value depends on retrieval accuracy, citation fidelity, and how well it handles conflicting or incomplete medical evidence.
Premium publisher partnerships
Relationships with NEJM, JAMA Network, Nature, and Cochrane bring figures, tables, and full-text findings into the platform. These licenses create differentiated content access, while also adding renewal costs and dependency on publishing partners.
Guideline-aware oncology support
The NCCN collaboration adds treatment algorithms used by oncology professionals. Guideline content is especially valuable because care pathways change over time and vary by cancer type, stage, biomarkers, and patient context.
From search tool to clinical workflow
The long-term opportunity is deeper integration into hospital, practice, and documentation workflows. That could make OpenEvidence more useful and sticky, but it raises the bar for privacy, security, auditability, and medical-governance controls.
Before investing, verify which milestones have been completed, how they affect revenue and cash requirements, and whether the offered security reflects the rights and valuation of the company’s most recent primary financing.
Key Risks
Clinical Accuracy and Liability
Clinicians may rely on OpenEvidence when making consequential decisions. Incomplete, outdated, or incorrect synthesis could harm patients, create liability, and damage trust even when users remain responsible for judgment.
Privacy and Regulatory Compliance
Healthcare data and clinical workflows are governed by strict privacy, security, and professional requirements. A breach or compliance failure could restrict deployment and expose the company to penalties.
Source-Material Access
The product depends on continued access to high-quality medical literature and licensed content. Changes in publisher terms, data rights, or source availability can raise costs or weaken coverage.
Competitive AI Market
Medical publishers, health-information vendors, model providers, and new clinical AI companies can build competing tools. Distribution and trusted evidence may matter as much as model quality.
Valuation and Monetization
The $12 billion valuation assumes rapid adoption and durable monetization. If clinician usage does not convert into attractive enterprise, payer, publisher, or advertising economics, the valuation may compress.
Liquidity and Offering Structure
OpenEvidence remains private with no public date. Secondary buyers may face transfer restrictions, limited disclosure, SPV fees, and security rights that differ from the latest preferred round.
How to Buy OpenEvidence Pre-IPO Shares
- Confirm the company is still private. Check official company announcements, SEC records, and exchange listings.
- Confirm investor eligibility. Many U.S. private offerings are limited to accredited investors; access varies by jurisdiction.
- Verify the issuer and vehicle. Determine whether the offer is direct stock, a secondary sale, a fund interest, or an SPV.
- Compare security rights. Review share class, liquidation preference, voting, conversion, anti-dilution, and transfer provisions.
- Model the complete cost. Include platform fees, SPV expenses, carried interest, taxes, and settlement costs.
- Plan for illiquidity. Private shares may remain non-transferable for years and an IPO is not guaranteed.
Investor eligibility depends on the offering and jurisdiction. U.S. investors can review current SEC accredited-investor criteria.
Where to Buy OpenEvidence Pre-IPO Shares
Availability on private marketplaces changes with seller supply, company transfer restrictions, jurisdiction, and investor eligibility. Always verify the live offering rather than assuming that OpenEvidence shares are available.
MicroVentures
Featured
MicroVentures facilitates primary and secondary private-company offerings. Eligibility, minimums, fees, investment structure, and availability vary by offering; Regulation D opportunities are limited to accredited investors.
View Available Private-Market Opportunities
OpenEvidence availability is not guaranteed. Review the specific offering documents before investing.
| Platform | Typical Access Model | What to Verify |
|---|---|---|
| StartEngine Private | Late-stage private-company offerings | Current issuer availability, eligibility, minimum, fees, and vehicle structure |
| Forge Global | Private-company secondary marketplace and brokerage | Seller availability, accreditation, price, share class, and transaction costs |
| EquityZen | Private-company offerings that may use pooled vehicles | SPV terms, fees, minimum, economic rights, and transfer conditions |
| Rainmaker Securities | Broker-assisted private-company transactions | Security source, broker fees, settlement, and company approval |
| Hiive | Marketplace for private-company buyers and sellers | Indicative versus executable pricing, seller proof, and transfer restrictions |
| EquityBee | Employee-option financing and private-market exposure | Contract structure, economics, fees, and whether the investor receives shares or contractual rights |
| Augment | Private-market brokerage and secondary access | Issuer availability, accreditation, share class, fees, and settlement process |
OpenEvidence IPO Outlook
No completed public listing was identified for OpenEvidence as of 2026-08-31. A large late-stage round, hiring activity, secondary liquidity, or language in preferred-share documents can support an eventual-IPO thesis, but none substitutes for a filed registration statement and an effective listing.
Investors should monitor SEC filings, company governance, finance-leadership hires, audited financial reporting, tender offers, and any official exchange or company announcement. An IPO can be delayed, repriced, replaced by an acquisition, or never occur.
Frequently Asked Questions
Does OpenEvidence have a stock symbol?
No. OpenEvidence is private and does not have a public-market ticker.
What is OpenEvidence worth?
The latest disclosed valuation context in this research is $12 billion. That figure applies to a particular financing date and security and is not a guaranteed current common-share value.
Can retail investors buy OpenEvidence stock?
Not on a public exchange. Some eligible investors may find private shares or pooled exposure, but access, fees, rights, and transfer restrictions vary.
Will OpenEvidence go public?
Possibly, but there is no guaranteed timetable. Treat an IPO as an optional exit scenario rather than the investment’s base case.
Primary and Supporting Sources
Verified 2026-08-31. This article is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Private securities are speculative, may be unavailable in your jurisdiction, and can result in the loss of the entire investment.
